eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'sclc', 'nsclc', 'pembrolizumab', 'pdl']
adding a lag-3 protein in combination to pembrolizumab in front-line of nsclc (all pdl1): the tacti-002 trial. safety profile concerning. efficacy outcomes not exciting. in french we say: "bof". #asco22 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????